- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06145542
Sequences of Aerobic and Resistance Exercise and Cardio-metabolic Functions in T2D (ARRA)
Sequences of Aerobic and Resistance Exercise in Training and Their Effects on Cardio-metabolic Functions Among Type 2 Diabetes Patients - a Randomized Study
Study Overview
Status
Conditions
Detailed Description
Objectives:
This randomized study aims to explore the effects of aerobic and resistance training sequences on glycemic control among type 2 diabetes (T2D) patients through an 8-wk combined aerobic and resistance exercise training program.
Study Population:
A total of 56 participants with T2D aged 50-70 years (sex ratio approximately 1:1) with a course of type 2 diabetes of more than one year are included. Participants are residents of Nanjing Municipality, Jiangsu Province, China. Participants are recruited from the outpatients at Maigaoqiao Community Health Service Center, Qixia District, Nanjing, China or through online advertisement published on the official social media (WeChat) channels of the Health Service Center.
Randomization:
Participants are stratified by baseline hemoglobin A1c (HbA1c) and age, they are randomly assigned into two groups with a block size of 4. The study groups are: 1) aerobic before resistance training (AR group, n=28); 2) resistance before aerobic training (RA group, n=28).
Exercises intervention program:
Exercised program is designed to take place three times a week for a total of eight weeks. Exercise intervention is scheduled for approximately 70 minutes per session (30 minutes of aerobic and 30 minutes of resistance, no break between two types, 5-min of preparation and 5-min relaxation stretching movements before and after each intervention), performed between 8:00 to 11:00 or between 14:00 to 16:30, Monday through Saturday.
Target heart rate during aerobic exercise is set as resting heart rate (HR) + 40%-70% of heart rate reserve (HRR). Participants' HRR was calculated based on their resting HR and maximum heart rate (HRmax=208-0.7×age) as HRmax - HR. Heart rate monitors (OH1, Polar Oy, Oulu, Finland) are used during all exercise sessions to track exercise intensity and ensure that it remained within the specified range. Aerobic exercise is performed on bicycle ergometers for a continuous 30 minutes with a progressive intensity of 40%-70% HRR. Resistance level is set according to an adaptive training prior to the first intervention, pedal cadences are 50-60r/min.
Resistance exercise is conducted using a set of equipment including chest press/ row, leg extension/ curl, abdominal/ back, biceps/ triceps, inner/ outer thigh, and push/ pull machines. Prior to conducting the 1 repetition maximum (RM) testing for the major muscles of the upper and lower limbs, all participants receive proper instructions on how to use the equipment. The Brzycki 1-RM prediction equation is used to estimate the 1RM based on the recorded resistance and repetitions. All participants performe resistance exercise with a weight of 60%-80% 1RM. Movements on each machine are repeated 10-12 times per unit for a total of 4 units, with a-30 second break between units.
In all intervention sessions, participants in AR group complete aerobic exercise before starting resistance exercise, while participants in RA group performe two types of exercise in a reversed order. Participants are instructed to maintain their usual lifestyle but refrain from engaging in other forms of regular exercise throughout the intervention period.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Nanjing, Jiangsu, China, 210000
- Maigaoqiao Community Health Service Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Age 50-70 years;
- Type 2 diabetes diagnosed as: random blood glucose ≥11.1mmol/L (200mg/dL) or fasting blood glucose ≥7.0mmol/L (126mg/L) or oral glucose tolerance test (2h) ≥11.1mmol/L (200mg/dL) or glycated hemoglobin (HbA1c) ≥ 6.5%;
- The course of type 2 diabetes lasted for one year or longer;
- Willing to participate and sign the informed consent form voluntarily
Exclusion Criteria:
- Type 1 diabetes;
- Fasting blood glucose (FBG)>16.7mmol/L;
- Severe complications of diabetes such as acute infection, diabetic ketoacidosis, and plantar lesions;
- Severe kidney disease, cardiovascular and cerebrovascular diseases as identified by a specialist;
- Musculoskeletal, neurological, psychiatric or other disorders which limit the ability to exercise as identified by a specialist;
- Doing physical exercise regularly (≥ 3 times per week, at least 1 hour per session of moderate to vigorous activities);
- Currently under dietary program for weight loss;
- Systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg at rest;
- Abnormal electrocardiogram (rest and exercise);
- Other comorbidities or medications irrelevant to diabetes treatment that may influence glycemia during the past 6 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: AR group
aerobic exercise then resistance exercise in all training sessions
|
Exercise are performed 3 times/wk for 8 wks. Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve (HRR). Real-time heart rate monitors are worn by each participant during the session. Aerobic training session lasts for 30 minutes, with an additional 5-minute warm-up and 5-min relaxation training before and after the session, respectively. Participants perform resistance exercise on a set of strength training equipment. Load of resistance exercise is between 60-80% of repetition maximum (RM) in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 seconds. Between each two sets, there are 60 s of rest time. |
|
Active Comparator: RA group
resistance exercise then aerobic exercise in all training sessions
|
Exercise are performed 3 times/wk for 8 wks. Following a 5-min warm-up exercise, the participants perform resistance training on a set of equipment. Load of resistance exercise is set between 60-80% of repetition maximum in each set of exercise. Six different groups of resistance exercise (involving contractions and relaxations of biceps, triceps, pectoralis major, latissimus dorsi, quadriceps, and hamstrings) are conducted, with 6 sets of 10 repeated tasks in each group. Participants are instructed to finish each set of exercise task within 60 s. Between each two sets, there are 60 seconds of rest time. Aerobic training sessions are performed using cycle ergometers. Riding speed is 55-60 rotations/min, at an intensity between 50%-75% of heart rate reserve. Real-time heart rate monitors are worn during the entire session. Each aerobic training session lasts for 30 minutes, with an 5-minute relaxation training after the session. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fasting Glucose at Baseline
Time Frame: At week 0, within 7 days before the intervention starts
|
blood glucose level following overnight (12-h) fasting
|
At week 0, within 7 days before the intervention starts
|
|
Fasting Glucose at Follow-up
Time Frame: At week 9, within 7 days after the intervention completes
|
blood glucose level following overnight (12-h) fasting
|
At week 9, within 7 days after the intervention completes
|
|
Hemoglobin A1c (HbA1c) at Baseline
Time Frame: At baseline, within 7 days before the intervention starts
|
At baseline, the HbA1c level in blood among all participants
|
At baseline, within 7 days before the intervention starts
|
|
Hemoglobin A1c (HbA1c) at Follow-up
Time Frame: At week 9, within 7 days after the completion of the 8-week intervention
|
After intervention, the HbA1c level in blood among all participants
|
At week 9, within 7 days after the completion of the 8-week intervention
|
|
Continuous Glucose Monitoring at Baseline (Mean, sd, Lage)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (mean, sd, lage)
|
At baseline, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
|
At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (mean, sd, lage)
|
|
Continuous Glucose Monitoring at Baseline (Coefficient of Variation)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (cv)
|
At baseline, 14-day continuous glucose monitoring including mean glucose value, standard deviation (SD) of the glucose values, coefficient of variation (CV) of relative standard deviation, LAGE, TIR, TAR, TBR
|
At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (cv)
|
|
Continuous Glucose Monitoring at Baseline (Tir, Tar, Tbr)
Time Frame: At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (tir, tar, tbr)
|
At baseline, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
|
At baseline, within 14 days before the intervention starts, measurement lasts for 14 days (tir, tar, tbr)
|
|
Continuous Glucose Monitoring at Follow-up (Mean, sd, Lage)
Time Frame: at week 8-9
|
After intervention, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
|
at week 8-9
|
|
Continuous Glucose Monitoring at Follow-up (Coefficient of Variation)
Time Frame: at week 8-9
|
At baseline, 14-day continuous glucose monitoring including mean glucose value, standard deviation (SD) of the glucose values, coefficient of variation (CV) of relative standard deviation, LAGE, TIR, TAR, TBR
|
at week 8-9
|
|
Continuous Glucose Monitoring at Follow-up (Tir, Tar, Tbr)
Time Frame: at week 8-9
|
After intervention, 14-day continuous glucose monitoring including mean, sd, cv, lage, tir, tar, tbr
|
at week 8-9
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Yan Zhao, MD, PhD, Nanjing Sport Institute
- Principal Investigator: Xiao Tan, PhD, Zhejiang University
- Study Director: Lijun Wei, MD, Maigaoqiao Community Health Service Center
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RT-2023-17
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 2 Diabetes
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
ENBIOSIS BIOTECHNOLOGIESAydin Adnan Menderes University; Izmir University of Economics; Buca Seyfi Demirsoy... and other collaboratorsRecruitingType 2 Diabetes | Diabetes Mellitus Type 2Turkey (Türkiye)
-
University of MiamiSexual Medicine Society of North America Inc.Not yet recruitingType 2 Diabetes | Type 2 Diabetes (T2DM)United States
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
University of PennsylvaniaNational Institute on Aging (NIA); American Heart AssociationRecruitingType 2 Diabetes Mellitus | Type 2 Diabetes | Type II Diabetes Mellitus | Pre-diabetes | Pre-diabetic | Type II Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2DM) | Pre-diabetic StateUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
Clinical Trials on AR group: aerobic training before resistance training
-
University of BarcelonaCompleted
-
Riphah International UniversityCompletedHypertension | ObesePakistan
-
Memorial Sloan Kettering Cancer CenterNational Cancer Institute (NCI); Duke UniversityCompleted
-
Case Comprehensive Cancer CenterNational Institutes of Health (NIH)CompletedPhysical Activity Intervention to Reduce Functional Health Disparities Among Breast Cancer SurvivorsBreast Cancer | Physical ActivityUnited States
-
University of Illinois at ChicagoNational Heart, Lung, and Blood Institute (NHLBI)RecruitingCardiovascular Diseases | Vascular Diseases | HypertensionUnited States
-
Riphah International UniversityCompletedCardiovascular DiseasesPakistan
-
National Cardiovascular Center Harapan Kita Hospital...Completed
-
Nanjing University of Traditional Chinese MedicineGuangxi Medical University; Southeast University, ChinaUnknown
-
University of AarhusOxford Brookes UniversityCompleted
-
Universita di VeronaCompleted